Drug major Dr Reddy's Laboratories Tuesday said it has launched Colesevelam Hydrochloride tablets, used for lowering of cholesterol, in the US market.
The company has launched generic Colesevelam Hydrochloride tablets USP in the US market after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing.
The tablets are generic version of Daiichi Sankyo Inc's Welchol tablets, it added.
According to the IMS Health data, the Welchol brand and generic had the US sales of around USD 471 million MAT for the most recent 12 months ending in August 2018, Dr Reddy's Laboratories said.
Colesevelam Hydrochloride tablets along with diet and exercise, lower low-density lipoprotein cholesterol.
Shares of Dr Reddy's Laboratories closed at Rs 2,446.60 per scrip on the BSE, up 4.60 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app